Vitiligo, known as pale skin or leucoderma, is a dermatological disorder caused by a deficiency of the pigment melanin and characterized by the development of white spots on the skin. This condition tends to progress over time, resulting in larger patches of depigmentation on the skin, however, in some people, the patches may remain stable. It is an autoimmune physical disease, sometimes transmitted genetically from parent to child.

The symptoms of Vitiligo are patchy skin discoloration, discoloration of the hair on the scalp, and mucosal discoloration. Additionally, people with Vitiligo are more susceptible to other autoimmune diseases such as Addison’s disease and hypothyroidism. Long-term effects of Vitiligo are mental stress, skin cancer, iritis, and hearing loss due to loss of cochlear melanocytes. Depending on the severity of the patches, there are three types of Vitiligo namely generalized or non-segmental, segmental and mucous. Generalized Vitiligo is the most common type of Vitiligo in which white patches appear all over the body. In segmental vitiligo, the white patches are limited to one area, such as the hands or face.

Mucosal Vitiligo affects the lining of the mouth and genital areas. Furthermore, Vitiligo does not cause serious health problems; however, it can lead to physical complications such as sunburn, eye problems, and an increased chance of developing other autoimmune diseases. Also, medicinal treatments for Vitiligo are intended to restore an even skin tone, however they do not cure the disease permanently.

Download Free Sample Report-

The global vitiligo treatment market was estimated at $410.5 million in 2021 and is expected to hit $625.8 million by 2031, registering a CAGR of 4.3% from 2022 to 2031. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

Covid-19 scenario-

  • Decline in demand for corticosteroid during the pandemic impacted the global vitiligo treatment market negatively, especially during the initial period. Also, the majority of non-emergency medical services got postponed during the time.
  • However, the market has now got back on track.

The global vitiligo treatment market is analyzed across consulting type, distribution channel, drug class type, and region. The report takes in an exhaustive analysis of the segments and their sub-segments with the help of tabular and graphical representation. Investors and market players can benefit from the breakdown and devise stratagems based on the highest revenue-generating and fastest-growing segments stated in the report.

By type, the unsegmented segment accounted for nearly 90% of total market revenue in 2021 and is expected to dominate by 2031. The same segment would also project the fastest CAGR of 4.5% over the entire forecast period. Segmental segment is also analyzed through the report.

Based on distribution channel, the drugstore and retail pharmacy segment accounted for nearly three-fifths of the total market revenue in 2021 and is expected to dominate by 2031. The online providers segment, concurrently, would quote the fastest CAGR of 6.2% over the entire forecast period. Hospital Pharmacy segment is also studied through the market report.

Get Free Customization On this Report –

By drug class type, the corticosteroids segment garnered more than two-thirds of the global vitiligo treatment market in 2021, and would rule the roost by the end of 2031. The same segment would also display the fastest CAGR of 4.7% from 2022 to 2031. The calcineurin inhibitor segment is also assessed in the study.

Based on region, the global vitiligo treatment market across North America generated nearly two-fifths of the total market revenue in 2021, and is anticipated to retain the lionโ€™s share by 2031. The Asia-Pacific region, simultaneously, would showcase the fastest CAGR of 5.4% throughout the forecast period. The other provinces analyzed through the report include Europe and LAMEA.

The key market players analyzed in the global vitiligo treatment market report include Astellas Pharma Inc., Bristol-Mayers Squibb (Celegen), Bausch Health Companies Inc. (Bausch+Lomb Inc.), Dermavant Science Inc., Dr. Reddyโ€™s Laboratories Ltd, Incyte Corporation, Merck kGaA, Arcutis Biotherapeutics, Pfizer Inc., and Viatirs Inc. (Mylan N.V.). 

Leave a comment

Your email address will not be published. Required fields are marked *